Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of weekly Alpha-1 MP infusions in Japanese subjects with alpha1 antitrypsin deficiency
jRCT2080223139Phase 2Completed
- Sponsor
- Grifols
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Primary endpoint: Long-term safety of weekly Alpha-1 MP. Started Mar 2016; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on jRCT2080223139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223139.